Table 1.
Drugs taken during the study in the four groups.
| Drugn | Placebo (30 subjects) | Avanafil (31 subjects) | Blunorm forte + Avanafil (32 subjects) | Blunorm forte (30 subjects) |
|---|---|---|---|---|
| Anti-hypertensives n (%) | ||||
| Diuretic | 4 (13.3) | 3 (9.7) | 4 (12.5) | 2 (6.7) |
| ACE-I | 16 (53.3) | 13 (41.9) | 13 (40.6) | 11 (36.7) |
| Sartan | 10 (33.3) | 12 (38.7) | 14 (43.8) | 12 (40.0) |
| Ca-antagonist | 9 (30.0) | 10 (32.6) | 7 (21.9) | 9 (30.0) |
| β-blocker | 3 (6.7) | 2 (6.5) | 3 (9.4) | 1 (3.3) |
| Hypo-cholesterolemics n (%) | ||||
| Statin | 18 (60.0) | 20 (64.5) | 17 (53.1) | 21 (70.0) |
| Fibrate | 4 (13.3) | 5 (16.1) | 5 (15.6) | 7 (23.3) |
| Ezetimibe | 10 (33.3) | 5 (16.1) | 11 (34.4) | 8 (26.7) |
| Omega-3 | 6 (20.0) | 4 (12.9) | 5 (15.6) | 4 (13.3) |
| PCSK9-I | 5 (16.7) | 3 (9.7) | 3 (9.4) | 4 (13.3) |
| Anti-aggregants n (%) | ||||
| ASA | 5 (16.7) | 4 (12.9) | 7 (21.9) | 6 (20.0) |
| Clopidogrel | 1 (3.3) | 2 (6.5) | 0 (0.0) | 3 (6.7) |
| PPI n (%) | 6 (20.0) | 6 (19.4) | 7 (21.9) | 9 (30.0) |
| Anti-diabetics n (%) | ||||
| Sulphonylurea | 3 (6.7) | 2 (6.5) | 4 (12.5) | 4 (13.3) |
| Metformin | 22 (73.3) | 20 (64.5) | 24 (75.0) | 21 (70.0) |
| GLP1- RA | 5 (16.7) | 6 (19.4) | 5 (15.6) | 4 (13.3) |
| DPP4-I | 7 (23.3) | 9 (29.0) | 11 (34.4) | 10 (33.3) |
| SGLT2-I | 4 (13.3) | 5 (16.1) | 3 (9.4) | 5 (16.7) |
| Insulin | 2 (6.7) | 1 (3.2) | 0 (0.0) | 1 (3.3) |
n: number of patients; %: percentage of patients.
ACE-I, Angiotensin Converting Enzyme-Inhibitors; PCSK9-I, Proprotein Convertase Subtilisin/Kexin type 9-Inhibitors; PPI,
Proton Pump Inhibitors; GLP1-RA, Glucagon-Like Peptide 1- Receptor Agonists; DPP4-I, Dipeptidyl Peptidase 4-Inhibitors.